58 related articles for article (PubMed ID: 18078766)
21. FK-3000 isolated from Stephania delavayi Diels. inhibits MDA-MB-231 cell proliferation by decreasing NF-κB phosphorylation and COX-2 expression.
Xu HD; Cho SC; Bang MA; Bae CS; Choi Y; Li YC; Lim SK; Shim J; Park DH
Int J Oncol; 2015; 46(6):2309-16. PubMed ID: 25823424
[TBL] [Abstract][Full Text] [Related]
22. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
Malvezi AD; Panis C; da Silva RV; de Freitas RC; Lovo-Martins MI; Tatakihara VL; Zanluqui NG; Neto EC; Goldenberg S; Bordignon J; Yamada-Ogatta SF; Martins-Pinge MC; Cecchini R; Pinge-Filho P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6157-64. PubMed ID: 25092706
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.
Hakozaki M; Tajino T; Konno S; Kikuchi S; Yamada H; Yanagisawa M; Nishida J; Nagasawa H; Tsuchiya T; Ogose A; Abe M; Hojo H
PLoS One; 2014; 9(2):e88035. PubMed ID: 24516579
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
26. Pivotal regulatory network and genes in osteosarcoma.
Luo Y; Deng Z; Chen J
Arch Med Sci; 2013 Jun; 9(3):569-75. PubMed ID: 23847684
[TBL] [Abstract][Full Text] [Related]
27. Bone sarcomas: from biology to targeted therapies.
Gaspar N; Di Giannatale A; Geoerger B; Redini F; Corradini N; Enz-Werle N; Tirode F; Marec-Berard P; Gentet JC; Laurence V; Piperno-Neumann S; Oberlin O; Brugieres L
Sarcoma; 2012; 2012():301975. PubMed ID: 23226965
[TBL] [Abstract][Full Text] [Related]
28. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.
Liu DB; Hu GY; Long GX; Qiu H; Mei Q; Hu GQ
Acta Pharmacol Sin; 2012 May; 33(5):682-90. PubMed ID: 22504904
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.
Winfield LL; Payton-Stewart F
Future Med Chem; 2012 Mar; 4(3):361-83. PubMed ID: 22393942
[TBL] [Abstract][Full Text] [Related]
31. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
Sobolewski C; Cerella C; Dicato M; Ghibelli L; Diederich M
Int J Cell Biol; 2010; 2010():215158. PubMed ID: 20339581
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.
Hakozaki M; Hojo H; Sato M; Tajino T; Yamada H; Kikuchi S; Abe M
Virchows Arch; 2009 Dec; 455(6):517-26. PubMed ID: 19921253
[TBL] [Abstract][Full Text] [Related]
33. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
35. Targeting apoptosis pathways by Celecoxib in cancer.
Jendrossek V
Cancer Lett; 2013 May; 332(2):313-24. PubMed ID: 21345578
[TBL] [Abstract][Full Text] [Related]
36. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Chun KS; Surh YJ
Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
[TBL] [Abstract][Full Text] [Related]
37. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
